Anthracycline cardiotoxicity: from bench to bedside.
Anthracycline cardiotoxicity: from bench to bedside.
复制标题
DOI：
10.1200/jco.2007.14.9401
复制
发表时间：
2008-08-01
期刊：
影响因子：
--
通讯作者：
Sawyer DB
中科院分区：
文献类型：
--
作者：
Gianni L;Herman EH;Lipshultz SE;Minotti G;Sarvazyan N;Sawyer DB
蒽环类药物仍然是最广泛使用和最有效的抗癌药物之一。不幸的是，危及生命的心脏毒性继续损害其有效性。尽管经过四十多年的研究，蒽环类药物心脏毒性的致病机制尚未完全阐明。此外，新药和联合疗法往往会加剧毒性。第一届蒽环类药物心脏毒性国际研讨会于 2006 年秋季在意大利科莫举行，重点关注最先进的知识，并讨论了解决这些药物心脏毒性所需的研究。在这里，我们将这些讨论纳入更广泛的临床前和临床问题审查的框架中。
Anthracyclines remain among the most widely prescribed and effective anticancer agents. Unfortunately, life-threatening cardiotoxicity continues to compromise their usefulness. Despite more than four decades of investigation, the pathogenic mechanisms responsible for anthracycline cardiotoxicity have not been completely elucidated. In addition, new drugs and combination therapies often exacerbate the toxicity. The First International Workshop on Anthracycline Cardiotoxicity, held in fall 2006, in Como, Italy, focused on the state-of-the-art knowledge and discussed the research needed to address the cardiotoxicity of these drugs. Here, we incorporate these discussions into the framework of a broader review of preclinical and clinical issues.